8-K Announcements
6Material company update
Jun 15, 2026·SEC
Material company update
Jun 2, 2026·SEC
Material company update
May 28, 2026·SEC
Evommune, Inc.(EVMN)Earnings, Financials & Key Ratios
EVMN•NYSE
$13.34
Price updated Jul 7, 2026
- Revenue$13M+85.7%
- EBITDA-$80M-15.9%
- Net Income-$69M-3.1%
- EPS (Diluted)-2.18+4.0%
- Gross Margin100%+22.5%
- EBITDA Margin-612.94%+37.6%
- Operating Margin-623.62%+37.6%
- Net Margin-529.77%+44.5%
- ROE-224.59%
EVMN Price & Volume
Evommune, Inc. (EVMN) stock price & volume — 10-year historical chart
Loading chart...
Erratic Milestone Revenue Masks Structural Burn Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone execution failure
Key Thesis Takeaways
- Evommune operates as a high-velocity, pre-commercial biotechnology firm where R&D expenditures, reaching $20.4 million in 2025Q4, significantly outpace sporadic licensing-based revenue.
- The company's reliance on external equity financing to bridge its negative $242.8 million retained earnings position suggests a precarious long-term solvency profile.
- Investors should monitor the firm's ability to achieve clinical milestones, as the current business model lacks the recurring revenue necessary to offset its aggressive quarterly cash outflows.
Verdict Logic
the company's reliance on sporadic licensing revenue to cover R&D costs that reached $20.4 million in 2025Q4 presents an unsustainable financial trajectory for long-term investors.
EVMN Growth Metrics
Evommune, Inc. (EVMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-75.72%
5 Years-75.72%
3 Years-75.72%
Last Year-63.56%
EVMN Recent Earnings
Evommune, Inc. (EVMN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/4 qtrs (50%)●Beat Revenue 1/4 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.64+22.9%
$0.83
Rev
—
$722,167
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$1.43-74.4%
$0.82
Rev
—
—
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.78+4.5%
$0.82
Rev
—
—
Q4 2025
Dec 11, 2025Metric
Actual
Est
EPS
$8.07-32.7%
$6.08
Rev
$10M+200.0%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.64vs $0.83+22.9% | —vs $722,167 |
| Q2 2026 | Mar 5, 2026 | $1.43vs $0.82-74.4% | — |
| Q1 2026 | Feb 25, 2026 | $0.78vs $0.82+4.5% | — |
| Q4 2025 | Dec 11, 2025 | $8.07vs $6.08-32.7% | $10Mvs $3M+200.0% |
Based on last 4 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Evommune, Inc. (EVMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.34 | $449.16M | -6.12 | 85.71% | -529.77% | -224.59% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $58.01 | $295.54M | -2.28 | — | — | -61.81% | — |
Compare EVMN vs Peers
Evommune, Inc. (EVMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVMN SEC Filings & Documents
Evommune, Inc. (EVMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when EVMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVMN Frequently Asked Questions
Evommune, Inc. (EVMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Evommune, Inc.'s revenue?
Evommune, Inc. (EVMN) reported $10.0M in revenue for fiscal year 2025. This represents a 100% increase from $5.0M in 2023.
How fast is Evommune, Inc. growing?
Evommune, Inc. (EVMN) grew revenue by 85.7% over the past year. This is strong growth.
Is EVMN profitable?
Evommune, Inc. (EVMN) reported a net loss of $76.0M for fiscal year 2025.
Dividend & Returns
What is EVMN's return on equity?
Evommune, Inc. (EVMN) has a return on equity (ROE) of -224.6%. Negative ROE indicates the company is unprofitable.
What is Evommune, Inc.'s free cash flow?
Evommune, Inc. (EVMN) had negative free cash flow of $80.4M in fiscal year 2025, likely due to heavy capital investments.